NCT03632525View on ClinicalTrials.gov

Intravenous Iron in Adults With Cystic Fibrosis

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

March 27, 2020

Study Completion Date

October 26, 2021

Conditions
Cystic FibrosisIron-deficiency
Interventions
DRUG

Ferric carboxymaltose

Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).

Trial Locations (1)

Unknown

John Radcliffe Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03632525 - Intravenous Iron in Adults With Cystic Fibrosis | Biotech Hunter | Biotech Hunter